Mereo BioPharma Group plc (MREO) Fair Value 2026

MREO · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.2 /10

32 fundamental signals · 0 models active

Value Trap Risk

LOW (25/100)

Quick Summary — As of 2026-08-28, Mereo BioPharma Group plc (MREO) trades at $0.25. QOC: 5.2/10. Value Trap Risk: 25/100 (LOW). 0/13 models active.

Key Facts

Ticker
MREO
Price
$0.25
Quality Score
5.2/10
Value Trap Risk
25/100
Models Active
0/13
Last Updated
Strength: 0 independent models provide multi-angle coverage
Risk: Limited model coverage (0/13) may reduce confidence

What Fair Value Does Each Model Give MREO?

0 Intrinsic Value Models vs. Current Price ($0.25)

Core Models (Unlocked)
Model Fair Value Upside

All Models Active

All 0 models are displayed above.

What Is Mereo BioPharma Group plc (MREO) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Mereo BioPharma Group plc currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About MREO?

0 of 13 models are currently active for MREO. See which stocks rank higher →

How Does MREO Rank in Biotechnology?

Among 625 Biotechnology stocks, MREO ranks #274 by Quality of Company score. CirclFi's QOC score of 5.2/10 evaluates 32 fundamental signals. A score of 5.2 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

As a life sciences company, Mereo BioPharma Group plc operates in a sector where cash runway (months) is a critical driver of valuation. Investors evaluating MREO should weigh these sector-specific dynamics alongside our model-derived fair values.

Is MREO a Value Trap?

CirclFi's Value Trap algorithm assigns MREO a score of 25/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for Mereo BioPharma Group plc. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Mereo BioPharma Group plc's fundamental quality profile registers 5.2/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every MREO valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Mereo BioPharma Group plc Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

ALDXAldeyra Therapeutics, Inc.QOC 5.2CALCCalciMedica, Inc.QOC 5.1NEUPNeuphoria Therapeutics Inc.QOC 5.2ABOSAcumen Pharmaceuticals, Inc.QOC 5.1ALMSAlumis Inc.QOC 5.2XBITXBiotech Inc.QOC 5.1VERAVera Therapeutics, Inc.QOC 4.6BPTHBio-Path Holdings, Inc.QOC 3.4ORMPOramed Pharmaceuticals Inc.QOC 6.3EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: ALDX · CALC · NEUP · ABOS · ALMS · XBIT · VERA · BPTH · ORMP · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to MREO?

5 companies across all industries closest to MREO’s Quality of Company score of 5.2/10.

PMHSPolomar Health Services, Inc.QOC 5.2RMCFRocky Mountain Chocolate Factory, Inc.QOC 5.2ECTMECA Marcellus Trust IQOC 5.2SNDASonida Senior Living, Inc.QOC 5.2NVDANVIDIA CorporationQOC 10.0

Read investment analysis: PMHS · RMCF · ECTM · SNDA · NVDA

Where Does MREO Sit in CirclFi's Biotechnology Rankings?

MREO is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Mereo BioPharma Group plc’s Valuation?

What is Mereo BioPharma Group plc's intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Mereo BioPharma Group plc (MREO). The Quality of Company score is 5.2/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is MREO overvalued or undervalued right now?

At $0.25, 0 of 0 active models suggest MREO may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Mereo BioPharma Group plc's business model in Biotechnology.

What does a Quality of Company score of 5.2 mean for MREO?

Mereo BioPharma Group plc's QOC of 5.2/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on MREO?

CirclFi analyzes MREO with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is MREO a value trap in 2026?

Mereo BioPharma Group plc's Value Trap score is 25/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Mereo BioPharma Group plc (MREO) a Quality of Company score of 5.2/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/MREO/ · Methodology
Primary sources for this MREO valuation
  • Financial statements: Mereo BioPharma Group plc 10-K and 10-Q filings on SEC EDGAR (CIK 0001719714) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for MREO as of ; valuations recomputed .